Neurocrine Biosciences, Inc.
DE ˙ DB ˙ US64125C1099
134,65 € ↑0,30 (0,22%)
2026-06-03
AKTIENPREIS
SecurityDE:NB3 / Neurocrine Biosciences, Inc.
InstitutionAxa S.a.
Latest Disclosed Ownership5,789 shares
Latest Disclosed Value $ 762,643
Axa S.a. ownership in NB3 / Neurocrine Biosciences, Inc.

On May 15, 2026 - Axa S.a. filed a 13F-HR form disclosing ownership of 5,789 shares of Neurocrine Biosciences, Inc. (DE:NB3) valued at $646,921 USD as of March 31, 2026. The entity filed a previous 13F-HR on November 14, 2025 disclosing 0 shares of Neurocrine Biosciences, Inc.. The current value of the position is $779,489 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,789 5,789 763 0.2688
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -341,734 -100.00 0 -100.00
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 341,734 8,035 2.41 42,953 16.38 0.1234
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 333,699 35,995 12.09 36,907 -9.18 0.1212
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 297,704 28,532 10.60 40,637 31.03 0.1234
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 269,172 -14,850 -5.23 31,014 -20.68 0.0918
2025-02-25 2024-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 284,022 40,333 16.55 39,101 16.34 0.1163
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 284,022 40,333 39,101 0.1163
2024-05-15 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 243,689 127,478 109.70 33,610 119.51 0.1007
2024-07-16 2023-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 116,211 -2,718 -2.29 15,312 14.44 0.0494
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 116,211 -2,718 15,312 0.0300
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 118,929 31,664 36.28 13,380 62.58 0.0470
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 87,265 35,604 68.92 8,229 57.37 0.0273
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 51,661 -19,158 -27.05 5,229 -38.18 0.0180
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 70,819 -20,504 -22.45 8,459 -12.80 0.0305
2023-02-14 2022-09-30 13F/A-1 Neurocrine Biosciences COM 64125C109 91,323 -16,947 -15.65 9,699 -8.10 0.0382
2022-11-14 2022-09-30 13F Neurocrine Biosciences COM 64125C109 91,323 -16,947 9,700 0.0382
2023-02-14 2022-06-30 13F/A-1 Neurocrine Biosciences COM 64125C109 108,270 49,602 84.55 10,554 91.89 0.0391
2022-08-15 2022-06-30 13F Neurocrine Biosciences COM 64125C109 108,270 49,602 10,554 0.0391
2023-02-14 2022-03-31 13F/A-1 Neurocrine Biosciences COM 64125C109 58,668 58,668 5,500 0.0156
2022-05-13 2022-03-31 13F Neurocrine Biosciences COM 64125C109 58,668 58,668 5,500 0.0156
2022-02-14 2021-12-31 13F Neurocrine Biosciences COM 64125C109 0 -6,200 -100.00 0 -100.00
2021-11-15 2021-09-30 13F Neurocrine Biosciences COM 64125C109 6,200 0 0.00 595 -1.33 0.0017
2021-08-13 2021-06-30 13F/A-1 Neurocrine Biosciences COM 64125C109 6,200 4,125 198.80 603 198.51 0.0017
2021-08-13 2021-06-30 13F Neurocrine Biosciences COM 64125C109 6,200 4,125 603 0.0010
2021-05-14 2021-03-31 13F Neurocrine Biosciences COM 64125C109 2,075 -13,766 -86.90 202 -86.69 0.0006
2021-02-12 2020-12-31 13F Neurocrine Biosciences COM 64125C109 15,841 -54,215 -77.39 1,518 -77.47 0.0048
2021-02-11 2020-09-30 13F/A-1 Neurocrine Biosciences COM 64125C109 70,056 -20,255 -22.43 6,737 -38.85 0.0243
2020-11-13 2020-09-30 13F Neurocrine Biosciences COM 64125C109 70,056 -20,255 6,737 13,448.1212
2021-02-12 2020-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 90,311 10,111 12.61 11,018 58.74 0.0434
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 90,311 10,111 11,018 43,451.0909
2021-02-12 2020-03-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 80,200 6,108 8.24 6,941 -12.85 0.0347
2020-06-15 2020-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 80,200 0 6,941 0.0347
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 80,200 6,108 6,941 19,303.0404
2021-02-12 2019-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 74,092 74,092 7,964 0.0324
2020-02-18 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 74,092 74,092 7,964 32,426.6850
2019-02-13 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -68,822 -100.00 0 -100.00
2018-11-08 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 68,822 -14,730 -17.63 8,462 3.09 0.0310
2018-08-13 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 83,552 1,063 1.29 8,208 19.98 0.0315
2018-05-14 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 82,489 -65,221 -44.15 6,841 -40.31 0.0273
2018-02-13 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 147,710 -148 -0.10 11,461 26.49 0.0450
2017-12-01 2017-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 147,858 56,972 62.69 9,061 116.72 0.0390
2017-11-13 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 147,858 56,972 9,061
2017-08-10 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 90,886 -3,452 -3.66 4,181 2.35 0.0190
2017-05-11 2017-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 94,338 94,338 4,085 0.0184
2015-11-13 2015-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -289,707 -100.00 0 -100.00
2015-08-13 2015-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 289,707 0 0.00 13,836 20.27 0.0554
2015-05-13 2015-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 289,707 -52,446 -15.33 11,504 50.50 0.0474
2015-02-13 2014-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 342,153 -17,682 -4.91 7,644 35.56 0.0307
2014-11-13 2014-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 359,835 -2,310 -0.64 5,639 4.93 0.0241
2014-08-13 2014-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 362,145 54,677 17.78 5,374 8.57 0.0224
2014-05-13 2014-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 307,468 -31,813 -9.38 4,950 56.20 0.0215
2014-02-13 2013-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 339,281 57,058 20.22 3,169 -0.81 0.0142
2013-11-13 2013-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 282,223 257,227 1,029.07 3,195 856.59 0.0157
2013-08-12 2013-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 24,996 24,996 334 0.0018
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.